Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
IRIDEX Corporation (IRIX): Exploring the Path to a +300% Gain Toward $2.75

IRIDEX Corporation (IRIX): Exploring the Path to a +300% Gain Toward $2.75

Key Takeaways

  • The $2.75 target is not an analyst consensus. It is the published price objective of the single firm currently covering the stock, Alliance Global Partners, and is used here because there are too few analysts to form a meaningful average.
  • At roughly $0.69, reaching $2.75 would require a gain of about 300%, a very large move.
  • Analyst Scott Henry of Alliance Global Partners cut the target to $2.75 from $3.00 in May 2026, citing a "flattish" 2026 outlook, and reiterated the Buy rating in August 2026.
  • The main supporting factors are the Cyclo G6 glaucoma laser and the PASCAL pattern-scanning retina laser, which the analyst expects to drive revenue growth.
  • The biggest risks are flat-to-soft revenue, widening losses, a thin balance sheet with roughly $4.7 million in cash, and a market value near $12 million.
  • You can find more information about IRIX's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
  • Explore Trending AI Robots to monitor changing buy and sell signals across the market.

How the $2.75 Target Came About

Only one analyst firm currently publishes a price target for IRIX, so a true multi-analyst consensus cannot be calculated. Alliance Global Partners' Scott Henry initiated coverage on February 5, 2026 with a Buy rating and a $3.00 target, then lowered it to $2.75 on May 20, 2026 after the company's most recent results, describing the 2026 outlook as "flattish." The $2.75 figure was reiterated in August 2026. Because a single analyst cannot form a meaningful average, this article treats $2.75 as a publicly discussed price objective rather than a consensus, with the analyst's own target history effectively spanning $2.75 to $3.00.

Current Market Position and Path Toward the Target

The latest verified price is about $0.69, within a 52-week range of roughly $0.61 to $1.65. Reaching $2.75 would require upside of approximately 300% — a very large move, nearly four times the current price and well above the stock's 52-week high. The fundamentals show a company under pressure: trailing revenue of about $51.6 million, a net loss of roughly $3.6 million, EPS (earnings per share) of about -$0.20, and cash of approximately $4.7 million. A move toward $2.75 would likely depend on a return to revenue growth, meaningful loss reduction, and a substantial re-rating of the stock, rather than incremental improvement alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Support a Move Toward the Target

  • The analyst's thesis centers on the Cyclo G6 laser system for glaucoma and the PASCAL pattern-scanning laser for retinal indications, both seen as growth drivers.
  • Losses are expected to narrow: the covering analyst projects 2026 losses to shrink to about $0.12 per share, a substantial improvement from current levels.
  • The stock's depressed valuation means even modest operational progress could trigger a large percentage re-rating from a low base.
  • Glaucoma and diabetic eye disease represent large, recurring patient populations that support long-term device demand.

What Could Prevent the Target From Being Reached

  • Recent results disappointed, with revenue of roughly $13 million missing expectations and a loss per share of about $0.07 coming in far wider than forecast.
  • The company's own outlook has been described as "flattish," limiting near-term revenue momentum.
  • The analyst actually raised loss-per-share estimates after the latest results, a sign of deteriorating profitability expectations.
  • A thin cash position of about $4.7 million raises questions about funding runway and the potential for dilution.
  • As a micro-cap with modest liquidity, the stock can be volatile and sensitive to sector-wide shifts in healthcare sentiment.

Technical Levels and Market Structure

The 52-week high near $1.65 is the most relevant overhead level and sits far below the $2.75 target, meaning the stock would need to clear that prior peak first and sustain a breakout with no recent trading history to anchor it. The round $1.00 level represents an early psychological hurdle, while the 52-week low near $0.61 marks the key downside reference. With the price near the bottom of its range, the longer-term trend structure remains firmly lower.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, and the single target here appears consistent with that convention. Investors should monitor quarterly revenue, particularly for the Cyclo G6 and PASCAL product lines, changes to loss guidance, cash burn and any financing activity, and whether additional analysts initiate coverage — which would provide a broader, more reliable picture than one firm's estimate. From what I see, tracking these elements closely helps clarify whether the setup remains viable.

Using AI Tools for Deeper Analysis

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, the tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. For investors tracking volatile small-cap names like IRIX, automated signals can offer a timely complement to fundamental analysis. In my view, this kind of AI assistance has become a useful part of staying on top of names that move quickly on limited coverage.

Final Assessment

The $2.75 figure is a genuine, published price objective, but it reflects a single analyst's view rather than a consensus, and it demands a roughly 300% move from the current price near $0.69. The bullish case rests on renewed growth in the Cyclo G6 and PASCAL laser franchises and a sharp narrowing of losses, while the bearish case points to flat revenue, wider-than-expected losses, and a constrained cash position. Given the gap between the current price and the target, the outcome hinges less on near-term earnings than on a durable return to growth and a re-rating of the stock. Investors should watch upcoming results, analyst revisions, and any new coverage rather than treat $2.75 as an expectation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IRIX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IRIX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 06, 2026

IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for IRIX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -12%. POAS experienced the highest price growth at 235%, while STIM experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 10 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of light-based medical systems and delivery devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1212 Terra Bella Avenue
Phone
+1 650 940-4700
Employees
108
Web
https://www.iridex.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.